

Title (en)
STIMULATION, MODULATION AND/OR INHIBITION OF ENDOTHELIAL PROTEOLYTIC ACTIVITY AND/OR ANGIOGENIC ACTIVITY

Title (de)
STIMULIERUNG, MODULIERUNG UND/ODER HEMMUNG DER ENDOTHELIALEN PROTEOLYTISCHEN AKTIVITÄT UND/ODER ANGIOGENEN AKTIVITÄT

Title (fr)
STIMULATION MODULATION ET/OU INHIBITION DE L'ACTIVITE PROTEOLITHIQUE ENDOTHELIALE ET/OU DE L'ACTIVITE ANGIOINIQUE

Publication
EP 1011328 A4 20010516 (EN)

Application
EP 98940875 A 19980814

Priority
• US 9816816 W 19980814
• US 5586897 P 19970815

Abstract (en)
[origin: WO9908522A1] Vascular endothelial growth factor-B (VEGF-B) and vascular endothelial growth factor-C (VEGF-C) are angiogenic polypeptides. It has been shown that VEGF-B and -C are angiogenic in vitro especially in combination with bFGF. VEGF-C also increases plasminogen activator (PA) activity in bovine endothelial cell lines and this is accompanied by a concomitant increase in PA inhibitor-1. Addition of alpha-2-antiplasmin to bovine endothelial cells co-treated with bFGF and VEGF-C partially inhibits collagen gel invasion.

IPC 1-7
A01N 37/18

IPC 8 full level
C12N 15/09 (2006.01); **A61K 38/19** (2006.01); **A61K 38/57** (2006.01); **C07K 14/50** (2006.01); **C07K 14/52** (2006.01); **C07K 14/81** (2006.01); **C07K 16/22** (2006.01); **C07K 16/24** (2006.01); **C12N 5/07** (2010.01); **C12N 5/071** (2010.01); **C12N 15/12** (2006.01); **C12Q 1/68** (2006.01); **A61K 38/00** (2006.01)

CPC (source: EP KR)
A61K 38/1866 (2013.01 - EP KR); **C07K 14/503** (2013.01 - EP KR); **C07K 14/52** (2013.01 - EP KR); **C07K 14/8121** (2013.01 - EP); **C07K 16/22** (2013.01 - EP KR); **C07K 16/24** (2013.01 - EP KR)

Citation (search report)
• [Y] US 5073492 A 19911217 - CHEN CHUNG-HO [US], et al
• [Y] M.P. SEED: "Angiogenesis inhibition as a drug target for disease: an update", EXPERT OPINION ON INVESTIGATIONAL DRUGS, vol. 5, no. 12, December 1996 (1996-12-01), pages 1617 - 1637, XP000985478
• [Y] J. BENEFIELD, G. J. PETRUZZELLI ET AL.: "Regulation of the steps of Angiogenesis by human Head and Neck squamous cell carcinomas", INVASION AND METASTASIS, vol. 16, no. 6, 1996, pages 291 - 301, XP000985474
• [A] M.S. PEPPER ET AL.: "In vitro angiogenic and proteolytic properties of bovine lymphatic endothelial cells", EXPERIMENTAL CELL RESEARCH, vol. 210, no. 2, February 1994 (1994-02-01), pages 298 - 305, XP000985479
• [A] S. J. OLIVER, ET AL.: "Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: Reduction of vascular endothelial growth factor (VEGF)", CELLULAR IMMUNOLOGY, vol. 166, 1995, pages 196 - 206, XP000612503
• See references of WO 9908522A1

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 9908522 A1 19990225; AU 8905698 A 19990308; CA 2300964 A1 19990225; CN 1275050 A 20001129; EP 1011328 A1 20000628; EP 1011328 A4 20010516; JP 2001514867 A 20010918; KR 20010022887 A 20010326

DOCDB simple family (application)
US 9816816 W 19980814; AU 8905698 A 19980814; CA 2300964 A 19980814; CN 98810009 A 19980814; EP 98940875 A 19980814; JP 2000509282 A 19980814; KR 20007001491 A 20000214